Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 26
- Jun 29, 2024
Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer
Kasi, et. al.
Filter by
QS-21 STIMULON™ Adjuvant
Vaccine
Nov 3, 2011
Safety and Immunogenicity of Long HSV-2 Peptides Complexed with rhHsc70 in HSV-2 Seropositive Persons.
Wald, et al.
QS-21 STIMULON™ Adjuvant
The Lancet Infectious Diseases
Oct 1, 2011
Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial.
Asante, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Infectious Diseases
Jul 1, 2011
Effect of the Pre-Erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children.
Bejon, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Aug 11, 2011
Four Year Immunogenicity of the RTS,S/AS02(A) Malaria Vaccine in Mozambican Children During a Phase IIb Trial.
Aide, et al.
QS-21 STIMULON™ Adjuvant
Expert Review of Vaccines
Apr 1, 2011
Recent Clinical Experience With Vaccines Using MPL- And QS-21-Containing Adjuvant Systems.
Garçon, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Nov 17, 2011
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children.
RTS,S Clinical Trials Partnership, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Sep 15, 2016
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham, et al.
MK-4830 (ILT4 Antagonist)
Clinical Cancer Research
Oct 1, 2021
First-in-Class Anti-immunoglobulin – like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu, et al.
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells.
Gonzalez, et al.
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells.
Gonzalez, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR.
Gonzalez, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization.
Gonzalez, et al.